Premium
Very low birth weight infant vitamin D supplementation: double‐blind, randomized clinical efficacy trial (828.13)
Author(s) -
Taylor Sarah,
Wagner Carol,
Finch Carolyn,
Ebeling Myla,
Hollis Bruce
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.828.13
Subject(s) - medicine , vitamin d and neurology , bone mineral , parathyroid hormone , excretion , placebo , gestational age , urinary calcium , birth weight , endocrinology , calcium , gastroenterology , pregnancy , osteoporosis , biology , alternative medicine , pathology , genetics
Objective: To evaluate whether infants receiving a supplemental 400 IU/day above standard preterm infant vitamin D (vitD) supplementation differed in mineral and bone health from infants receiving placebo. Methods: Very low birth weight (VLBW) infants with plasma 25‐hydroxyvitamin D [25(OH)D] < 20 ng/ml (vitD deficiency) were enrolled within 3 days of birth and randomized to active (400 IU/day supplemental vitD) or placebo group until term age equivalent (TAE). At TAE, plasma 25(OH)D, parathyroid hormone (PTH), calcium, phosphorus, urinary calcium and phosphorus excretion, and femur and spine bone mineral content (BMC) and bone mineral density (BMD) were measured. Statistical analysis was by Chi‐square, Fisher exact, and Wilcoxon Rank Sum. Results: Thirty‐eight (19 each group) vitD‐deficient infants were enrolled and followed at TAE. Active and control groups did not significantly differ in gender, race, birth gestational age, days from birth to TAE visit, or 25(OH)D at entry (13.6 and 11.8 ng/ml). From birth to TAE, median total vitD intake was significantly different between active and placebo groups (942 IU/day and 525 IU/day) (p<0.0001). At TAE, active and placebo groups were not statistically different in vitD deficiency, 25(OH)D status (32.9 and 28.9 ng/ml), calcium, phosphorus, PTH, urinary calcium excretion, urinary phosphorus excretion, and femur and spine BMC and BMD. Conclusions: VLBW infants receiving an additional 400 IU/day vitD received significantly higher vitD intake, but had no difference in vitD status, mineral homeostasis, or bone mineralization at term age. Grant Funding Source : Supported by NIH K23 RR021891 and RR1070